The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

COVID-19 infection is not associated with immediate changes in multiple sclerosis symptom severity or disability.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

A recent study finds health care spending in the United States reached $4.9 trillion and increased 7.5 percent in 2023.

Higher FT4 levels were associated with increased risks for knee OA prevalence, severity, and progression, especially among patients with greater joint loading.

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.

Black children are suspected to have experienced child abuse at higher rates than children of other racial and ethnic backgrounds.

Alcohol consumption was associated with lower levels of axSpA disease activity and spinal pain, but may be linked to ...

The FDA has granted Fast Track designation to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.

A brief outpatient rehabilitation program with a cognitive and behavioral approach is effective for patients with post-COVID-19 condition.

HealthDay News — Substance use among adolescents has continued to hold steady at lowered levels for the fourth year in a row, according to the U.S. National Institutes of Health (NIH)-funded ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of ...